Experimental cancer treatments for advanced stages are more effective than previously thought. Some oncology practitioners believe that experimental drugs are harmful - they give false hope to patients because of its low efficiency (long anticipated effectiveness of the experimental treatment with special drugs produced in Canadian pharmacy only at the level of 4-6% of cases). Patients in the final stage of the disease should have greater access to information about the experimental treatment programs, and, accordingly, they and their families should have the right to know what their real chances, with a particular treatment strategy. Scientists believe that the involvement of cancer patients even in the early stages of clinical trials can be very useful for them. Besides, the search for a way out of the situation means continuing the fight against the disease. It is characterized by academic phrase "treatment of metastatic cancer still remains palliative, with a very low probability of complete remission and cure the disease."

Work package 6


  • Provide dedicated management resource on a day-to-day basis to ensure that this project meets its objectives within its budget and timescale
  • Ensure the best return on investment for the EC funding.
  • Establish a functional management structure to ensure efficient communication between the participants in the project.
  • Identify potential problems at an early stage and provide timely and effective solutions.


The overall management is provided by the coordinator, who is supported by administrative resources required to oversee the project as a whole. The coordinator has full responsibility for the overall project coordination, financial matters and daily management. The coordinator will ensure a smooth and efficient flow of research and will serve as the sole contact point for the European Commission. The Partner 2 PHG will assist the coordinator particularly by providing timely information obtained by monitoring the clinical trial and thereby to identify possible complications to project progress in regular meetings with the coordinator.

Reporting to the European Commission
Accepting the intermediate and final reports as prepared by the Work Package Leaders prior to its submission to the European Commission. The coordinator will submit reports to the EC including a publishable summary of work progress, explanation of the use of resources and a financial statement 60 days after each reporting period. In addition, the coordinator will submit a final report to the EC 60 days after project ending.

Information flow in the consortium
The coordinator will be in charge of internal and external reviews and the distributing of information to the partners. The coordinator will furthermore ensure that legal and ethical issues are dealt with properly.

Consortium meetings
The coordinator will plan and prepare the kick-off prior to start of the clinical trial and in the following annual consortium meetings

Monitoring of scientific progress
A cornerstone of management is quality and safety assurance of the clinical and translational research and the coordinator will hence perform an ongoing monitoring of all deliverables resulting from the project.

Gender aspect in IMMOMEC
Special management effort will be put into the recruitment and retention of female researchers including physicians, biologists, and technologists on pre- and postgraduate levels.